Philip Cheng

Advising one of the world's largest private companies on the massive corporate restructuring of its newly acquired businesses throughout China and Asia.

Advising world-leading medical device and technology enterprise in its 'go-to-market' strategy in China and subsequent establishment of distribution facilities in Shanghai.

Advising NYSE-listed technology company on strategic alliance with Chinese railway on development of new-generation energy storage devices for the China market.

Acting for a German heavy equipment manufacturer on a labour strike in Shanghai involving more than 300 workers and handling subsequent employee breaches of restrictive covenants.

Acting for a U.S. Fortune 500 financial services company on the roll-out of its entire employment program in China and on operational matters since establishment of its data center.

Advising international materials handling manufacturer on two-year shareholder dispute and divestiture of its interests in a joint venture in Zhejiang.

Advising leading household name in pharma and consumer health products on the divestiture of several consumer brands throughout Asia and the acquisition of orthopedics business in China.

Advising one of the world's largest medical testing companies in its China consolidation through a combination of statutory merger and asset transfer arrangements.

Advising top pharma multinational on the termination of high-level executives for fraud and potential corrupt practices involving concertive actions with hospital administrations, vendors and other employees.

Advising U.S. conglomerate on the build-out of its petro-chemicals facilities and resolving corporate structuring, financing, permit and licensing, vendor contracting, construction, employment and IP protection issues.

Advising U.S. data company on data protection issues arising from the sourcing and collection of information within China and handling the shut-down and termination of certain marketing businesses and staff.